Internal Medicine · Clarkston, MI
NPI
1942210299
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
7188 N Main St
Clarkston, MI, 48346
Phone (248) 625-1600
Groups this clinician bills Medicare through
Medicare paid, 2024
$324K
4,862 services
Medicare patients, 2024
701
Average age 76
Drug cost, 2024
$1.1M
9,808 prescriptions
Company payments, 2025
$703
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bashar Okka was code 99214 (office e&m - established), 1,041 times for 438 patients. In total Bashar Okka billed 4,862 services in 100 codes, and Medicare paid $324K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,041 | 438 | $84.58 | $88K |
| 99213 Office E&M - Established | Office | 560 | 364 | $63.43 | $36K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 325 | 13 | $0.23 | $74.39 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 289 | 289 | $129.73 | $37K |
| 99497 Care Management/Coordination | Office | 239 | 239 | $78.50 | $19K |
| 99232 Hospital E&M - Subsequent | Facility | 209 | 101 | $62.36 | $13K |
| G0008 Administration of influenza virus vaccine | Office | 204 | 199 | $32.71 | $6,673 |
| 90653 Vaccine Product | Office | 199 | 199 | $81.00 | $16K |
| G0447 Face-to-face behavioral counseling for obesity, 15 minutes | Office | 159 | 79 | $25.33 | $4,028 |
| 81002 Clinical Chemistry | Office | 142 | 102 | $3.31 | $471 |
| 90480 Vaccine Administration | Office | 114 | 108 | $43.25 | $4,930 |
| 91320 Vaccine Product | Office | 114 | 108 | $144.25 | $16K |
| G0009 Administration of pneumococcal vaccine | Office | 111 | 111 | $32.71 | $3,631 |
| 90677 Vaccine Product | Office | 106 | 106 | $287.76 | $31K |
| 87804 Immunoassay | Office | 72 | 65 | $16.22 | $1,168 |
By year: 2022 $278K for 3,971 services; 2023 $281K for 4,033 services; 2024 $324K for 4,862 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 142 | 102 | $3.31 | $471 |
| 87804 Immunoassay | 72 | 65 | $16.22 | $1,168 |
| 87811 Immunoassay | 60 | 56 | $39.87 | $2,392 |
| 87635 COVID Specific | 39 | 37 | $50.28 | $1,961 |
Medicare prescription drug claims, 2024
In 2024, the drug Bashar Okka prescribed most often to Medicare patients was Atorvastatin Calcium, with 675 prescriptions and refills. In total Bashar Okka wrote 9,808 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 675 | 1,863 | 197 | $10K |
| Losartan Potassium Generic | 476 | 1,313 | 152 | $7,283 |
| Amlodipine Besylate Generic | 472 | 1,304 | 144 | $4,022 |
| Levothyroxine Sodium Generic | 422 | 1,140 | 112 | $5,502 |
| Metoprolol Succinate Generic | 383 | 1,075 | 110 | $6,792 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 296 | 812 | 81 | $7,302 |
| Lisinopril Generic | 259 | 768 | 74 | $2,491 |
| Metformin Hcl Generic | 254 | 725 | 71 | $3,085 |
| Omeprazole Generic | 250 | 706 | 77 | $3,518 |
| Tamsulosin Hcl Generic | 238 | 648 | 71 | $4,548 |
| Rosuvastatin Calcium Generic | 236 | 677 | 72 | $4,616 |
| Simvastatin Generic | 234 | 664 | 68 | $2,295 |
| Hydrochlorothiazide Generic | 229 | 631 | 73 | $1,166 |
| Metoprolol Tartrate Generic | 162 | 415 | 44 | $1,513 |
| Furosemide Generic | 160 | 394 | 53 | $1,156 |
Brand drugs: 1,411 claims; generic drugs: 8,323 claims; opioid claims: 59.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bashar Okka $703 ($703 in general payments such as food, travel and fees) from 11 companies. The largest payer was Novo Nordisk Inc with $235.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 13 | $235 |
| Lilly USA, LLC LLY | 6 | $106 |
| Amgen Inc. AMGN | 3 | $72.14 |
| Pfizer Inc. PFE | 4 | $69.94 |
| GlaxoSmithKline, LLC. GSK | 3 | $60.19 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $46.1 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $31.51 |
| Abbott Laboratories ABT | 1 | $23.9 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $20.83 |
| Abbvie Inc. ABBV | 1 | $19.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.